Prostate Treatment Articles & Analysis
30 news found
This is like other cancers such as kidney and breast cancer, where treating the cancer while preserving the healthy tissue is the first consideration for treatment rather than full nephrectomy or mastectomy. Men with localized intermediate risk prostate cancer, meaning cancer has not spread from the prostate, would benefit most from focal ...
We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a ...
Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. Darolutamide, which is jointly ...
ByBayer AG
The study enrolled 478 patients who had received prior treatment with one or two lines of endocrine therapy, including a CDK 4/6 inhibitor. ...
“Now, as the new Chair in Translational Oncology, my laboratory will continue to work to develop ways to block the spread of cancer and improve the diagnosis and treatment of prostate cancer for men in Alberta and beyond.” The Edmonton-based Bird Dogs have passionately supported prostate cancer research for over a decade in memory ...
Prostatitis is a disease characterized by the presence of inflammation and/or infection localized in the prostate gland. ...
(TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment ...
The group is comprised of five experienced physicians with extensive experience using Cesium-131 monotherapy for permanent prostate brachytherapy who came together to form the advisory group. Commenting on the presentations, Isoray CEO Lori Woods said, “Long-term outcomes have demonstrated the significance of Cesium-131 brachytherapy for prostate cancer ...
Health Technology Wales (HTW) has published guidance recommending the routine adoption of Extreme Hypofractionated Radiotherapy (EHFRT) for the treatment of localised prostate. In the UK, prostate cancer is the most common cancer in men and in Wales, more than 2,500 men each year are diagnosed with prostate cancer. Radiotherapy ...
“Bayer remains dedicated to addressing unmet needs in prostate cancer treatment for various stages of the disease,” said Christine Roth, Member of the Executive Committee of Bayer’s Pharmaceutical Division and Head of the Oncology SBU at Bayer. ...
ByBayer AG
Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner. Dr. Pankaj Jain at Arizona Urology said, “With our goal to offer the most advanced prostate cancer diagnostics and treatment ...
In clinical partnership with Promaxo, we look forward to optimizing clinical workflow for office-based MRI guided biopsies in our high volume practice, and to collaborating on prostate cancer treatments, including brachytherapy and post placement confirmatory scans of hydrogel with Promaxo's MRI ...
The published article on the study, Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution, was authored by Joshua L. ...
This includes another Phase III trial in mHSPC (ARANOTE) as well as an ANZUP-led international co-operative group Phase III trial, evaluating darolutamide as an adjuvant treatment for localized prostate cancer with very high risk of recurrence (DASL-HiCaP, ANZUP1801). ...
ByBayer AG
RP is currently the gold-standard surgical treatment for intermediate-risk prostate cancer. RP effectively controls disease, but carries risk of significant side effects such as long-term erectile dysfunction and urinary incontinence. ...
FDA cleared for in-office use, the Company’s single-sided MRI system with AI based imaging empowers practices and hospitals to accurately and seamlessly guide prostate interventions under the Promaxo scanner. “Our technology enables safe and effective point of care diagnostic biopsies and treatment of cancers, overcoming limitations of traditional ...
Despite this treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. ...
ByBayer AG
Oczachowski is the chairman and CEO of EDAP TMS, a French medtech company that makes a robotic high intensity focused ultrasound (HIFU) system for prostate cancer treatment. HIFU has changed the game in prostate cancer, leaving the prostate intact and only destroying the cancer, making it possible for men to retain their sex ...
ByEDAP TMS
MiraDx, in collaboration with the UCLA Jonsson Comprehensive Cancer Center, is conducting a clinical trial to validate a novel prostate cancer biomarker panel designed to help assess patients who were at a greater risk of having long-term toxicity in response to their radiation treatment, to help guide treatment decisions. ...
ByMiraDx
Because Cesium-131 seeds were not available as a treatment until 2004, long-term outcomes following Cesium-131 prostate brachytherapy seeds have only recently been available. ...